Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Consensus Recommendation of “Reduce” by Analysts

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) have been given a consensus rating of “Reduce” by the seven research firms that are covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $14.80.

A number of research firms recently weighed in on IART. Wall Street Zen upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 29th. Wells Fargo & Company dropped their price objective on Integra LifeSciences from $13.00 to $12.00 and set an “equal weight” rating for the company in a research note on Friday. Finally, Truist Financial reissued a “hold” rating and issued a $13.00 price target (down from $15.00) on shares of Integra LifeSciences in a report on Monday, November 3rd.

Institutional Trading of Integra LifeSciences

Hedge funds have recently bought and sold shares of the stock. Rubric Capital Management LP increased its holdings in shares of Integra LifeSciences by 1.3% in the fourth quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock worth $96,304,000 after purchasing an additional 100,000 shares during the last quarter. Invesco Ltd. increased its stake in Integra LifeSciences by 0.9% in the 4th quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock worth $43,754,000 after acquiring an additional 31,931 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Integra LifeSciences by 9.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock worth $45,634,000 after acquiring an additional 267,134 shares during the last quarter. State Street Corp raised its holdings in shares of Integra LifeSciences by 0.8% during the 4th quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock worth $34,933,000 after acquiring an additional 21,717 shares in the last quarter. Finally, Paradigm Capital Management Inc. NY boosted its position in shares of Integra LifeSciences by 5.3% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 2,664,998 shares of the life sciences company’s stock valued at $33,099,000 after acquiring an additional 135,198 shares during the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Trading Down 2.2%

NASDAQ:IART opened at $11.08 on Monday. The company has a 50 day simple moving average of $11.96 and a two-hundred day simple moving average of $13.18. The company has a market cap of $863.10 million, a PE ratio of -1.66 and a beta of 1.02. The company has a current ratio of 2.54, a quick ratio of 1.46 and a debt-to-equity ratio of 1.66. Integra LifeSciences has a 12 month low of $10.60 and a 12 month high of $24.36.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Thursday, February 26th. The life sciences company reported $0.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.04. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The business had revenue of $434.93 million during the quarter, compared to the consensus estimate of $429.62 million. During the same period in the previous year, the company posted $0.97 EPS. The business’s quarterly revenue was down 1.7% compared to the same quarter last year. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. Research analysts forecast that Integra LifeSciences will post 2.45 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.